港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

藥捷安康-B

8.805

+0.2653.10%

成交量：336.30萬

成交額：2,941.79萬

市值：35.92億

市盈率：-9.85

高：9.000

開：8.550

低：8.350

收：8.540

52周最高：246.000

52周最低：8.350

股本：4.08億

香港流通股本：3.13億

量比：1.24

換手率：1.07%

股息：- -

股息率：- -

每股收益(LYR):-0.894

淨資產收益率：-36.78%

總資產收益率：-20.32%

市淨率：3.48

市盈率(LYR):-9.85

市銷率: 86.17

資料載入中...

總覽公司新聞資訊公告

藥捷安康-B回購52,500股股份，涉資約45.87萬港元

港股異動 | 藥捷安康-B(02617.HK)升逾4% 捷恩泰®已於多個省份開出首批臨床處方

藥捷安康-B回購5,500股並發行660,000股H股，已發行股本變動

藥捷安康-B(02617)10月22日耗資約4.72萬港元回購5500股

藥捷安康-B（02617）披露捷恩泰®進入全國商業化銷售階段

藥捷安康-B(02617)：捷恩泰®已於多個省份開出首批臨床處方全國多地DTP藥房同步完成鋪貨

藥捷安康-B：Yochanra將於2026年9月17日啓動全國商業化供應

藥捷安康-B：Yochanra獲國家藥監局附條件批准，用於晚期膽管癌治療

藥捷安康－Ｂ(02617)股價下跌5.072%，現價港幣$8.61

阿斯达克财经

藥捷安康－Ｂ(02617)股價上升5.036%，現價港幣$9.595

阿斯达克财经

藥捷安康－Ｂ(02617)股價上升5.065%，現價港幣$10.58

阿斯达克财经

藥捷安康-B更新9月股份變動月報表，股本保持穩定

藥捷安康－Ｂ(02617)股價上升5.04%，現價港幣$10.63

阿斯达克财经

生物醫藥板塊強勢勁方醫藥-B（02595）漲8.01% 機構指醫藥工業「十五五」規劃有標誌性意義

藥捷安康-B2026年中期營收0.35億元，經調整淨虧損0.95億元

港股異動 | 藥捷安康-B(02617)升逾11% 替恩戈替尼mCRPC中國II期臨床完成首例給藥

藥捷安康(02617.HK)替恩戈替尼獲納入CSCO膽道惡性腫瘤診療指南

阿斯达克财经

藥捷安康－Ｂ(02617)股價上升5.184%，現價港幣$10.55

阿斯达克财经

藥捷安康-B：捷恩泰獲納入CSCO膽道惡性腫瘤診療指南(2026)

藥捷安康-B（02617）完成替恩戈替尼聯合NHT治療mCRPC中國Ⅱ期臨床首例給藥

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/02617/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"藥捷安康-B","latestPrice":8.805,"timestamp":1792742888143,"preClose":8.54,"halted":0,"volume":3363000,"delay":0,"changeRate":0.031030444964871264,"floatShares":313000000,"shares":408000000,"eps":-0.8936706478351907,"marketStatus":"未開盤","change":0.265,"latestTime":"10-23 16:08:08","open":8.55,"high":9,"low":8.35,"amount":29417855,"amplitude":0.076112,"askPrice":8.825,"askSize":8500,"bidPrice":8.805,"bidSize":8000,"shortable":3,"etf":0,"ttmEps":-0.7908679503909284,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":8.54,"openAndCloseTimeList":[[1792719000000,1792728000000],[1792731600000,1792742400000]],"volumeRatio":1.2356247932641409,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":313000000,"roa":"-20.32%","roe":"-36.78%","lyrEps":-0.893671,"volumeRatio":1.2356247932641409,"shares":408000000,"dividePrice":0,"high":9,"amplitude":0.076112,"preClose":8.54,"low":8.35,"week52Low":8.35,"pbRate":"3.48","psRate":"86.17","week52High":246,"institutionHeld":0,"latestPrice":8.805,"committee":-0.030303,"eps":-0.8936706478351907,"divideRate":0,"volume":3363000,"delay":0,"ttmEps":-0.7908679503909284,"open":8.55,"prevYearClose":114.9,"prevWeekClose":9.275,"prevMonthClose":10.94,"prevQuarterClose":10.94,"fiveDayClose":9.135,"twentyDayClose":10.61,"sixtyDayClose":9.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-10-15","current":-11.133338,"percent":0.978462,"low":-380.446233,"twenty":-177.773201,"median":-66.97175,"eighty":-13.514835,"high":-10.87103,"avg":-102.888789,"sd":96.131647,"marketCap":3720398962},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-28","current":-13.544101,"twenty":-206.454369,"median":-79.928564,"eighty":-37.623415,"marketCap":4242353783},{"date":"2026-09-04","current":-13.213217,"twenty":-200.748681,"median":-72.756691,"eighty":-35.040401,"marketCap":4140374124},{"date":"2026-09-11","current":-12.187879,"twenty":-194.548173,"median":-71.729981,"eighty":-33.11771,"marketCap":3824237184},{"date":"2026-09-18","current":-13.02239,"twenty":-188.179892,"median":-71.163303,"eighty":-16.078674,"marketCap":4091423888},{"date":"2026-09-25","current":-13.026466,"twenty":-182.801065,"median":-69.75013,"eighty":-14.040359,"marketCap":4084904388},{"date":"2026-10-02","current":-13.90794,"twenty":-181.844152,"median":-68.633717,"eighty":-13.915844,"marketCap":4365919745},{"date":"2026-10-09","current":-13.514835,"twenty":-180.193948,"median":-67.810296,"eighty":-13.738942,"marketCap":4247811842},{"date":"2026-10-15","current":-11.815946,"twenty":-177.773201,"median":-66.97175,"eighty":-13.514835,"marketCap":3720398962}],"updateTime":1792951741596},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1197503780","title":"藥捷安康-B回購52,500股股份，涉資約45.87萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197503780","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197503780?lang=zh_tw&edition=fundamental","pubTime":"2026-10-23 17:07","pubTimestamp":1792746437,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年10月23日公告披露，公司于当日通过香港联交所场内回购股份52,500股，约占现有已发行股份的0.02%。本次回购价格区间为每股8.55港元至8.79港元，合计耗资约45.87万港元。回购完成后，公司已发行股份总数仍为313,347,673股，其中不包括库存股份的已发行股份数为312,571,673股，库存股份数增至776,000股。公司表示，本次回购已获得董事会正式授权，并遵守了香港联交所相关上市规则及适用的法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B回购52,500股股份，涉资约45.87万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677494364","title":"港股異動 | 藥捷安康-B(02617.HK)升逾4% 捷恩泰®已於多個省份開出首批臨床處方","url":"https://stock-news.laohu8.com/highlight/detail?id=2677494364","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677494364?lang=zh_tw&edition=fundamental","pubTime":"2026-10-23 14:26","pubTimestamp":1792736810,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197898257","title":"藥捷安康-B回購5,500股並發行660,000股H股，已發行股本變動","url":"https://stock-news.laohu8.com/highlight/detail?id=1197898257","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197898257?lang=zh_tw&edition=fundamental","pubTime":"2026-10-22 20:25","pubTimestamp":1792671947,"startTime":"0","endTime":"0","summary":"2026年10月22日，药捷安康(南京)科技股份有限公司公告显示，公司近期进行了H股回购及新股增发操作，已发行股本与库藏股数相应变动。根据公告，2026年10月15日，公司依据2026年6月18日采纳的H股股份奖励计划，向相关参与人发行660,000股新H股，约占该次发行前公司已发行股份总数的0.21%。上述回购股份将以库藏股份形式持有。回购完成后，公司将于2026年11月21日之前暂缓开展新股发行或进一步出售、转让库藏股的相关事宜。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B回购5,500股并发行660,000股H股，已发行股本变动","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677680969","title":"藥捷安康-B(02617)10月22日耗資約4.72萬港元回購5500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677680969","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677680969?lang=zh_tw&edition=fundamental","pubTime":"2026-10-22 20:23","pubTimestamp":1792671806,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，2026年10月22日耗资约4.72万港元回购5500股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1511074.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189695147","title":"藥捷安康-B（02617）披露捷恩泰®進入全國商業化銷售階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1189695147","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189695147?lang=zh_tw&edition=fundamental","pubTime":"2026-10-22 12:06","pubTimestamp":1792641964,"startTime":"0","endTime":"0","summary":"2026年10月22日，药捷安康（南京）科技股份有限公司发布自愿性公告，披露核心产品捷恩泰的最新商业化进展。公司公告显示，捷恩泰首批产品已于2026年9月9日完成生产并出厂；9月17日，首批产品通过商业渠道发货至全国各地药房，并在北京大学肿瘤医院开出全国首张处方，标志着捷恩泰正式进入国内商业化销售阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677980435","title":"藥捷安康-B(02617)：捷恩泰®已於多個省份開出首批臨床處方 全國多地DTP藥房同步完成鋪貨","url":"https://stock-news.laohu8.com/highlight/detail?id=2677980435","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677980435?lang=zh_tw&edition=fundamental","pubTime":"2026-10-22 12:05","pubTimestamp":1792641935,"startTime":"0","endTime":"0","summary":"2026年9月9日，捷恩泰首批产品已完成生产并顺利出厂。2026年9月17日，捷恩泰首批产品正式从商业渠道发货，发往全国各地药房，正式开启全国商业化供应;同日，捷恩泰在北京大学肿瘤医院开出全国首张处方，标志着捷恩泰在国内正式进入商业化销售阶段。近期，捷恩泰在北京、上海、广东、江苏等多个省份开出首批临床处方，全国多地DTP药房同步完成铺货。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1510598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","DTP","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173233438","title":"藥捷安康-B：Yochanra將於2026年9月17日啓動全國商業化供應","url":"https://stock-news.laohu8.com/highlight/detail?id=1173233438","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173233438?lang=zh_tw&edition=fundamental","pubTime":"2026-10-22 12:02","pubTimestamp":1792641729,"startTime":"0","endTime":"0","summary":"药捷安康-B（TRANSTHERA-B）宣布，Yochanra定于2026年9月17日正式开启全国范围的商业化供应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191472032","title":"藥捷安康-B：Yochanra獲國家藥監局附條件批准，用於晚期膽管癌治療","url":"https://stock-news.laohu8.com/highlight/detail?id=1191472032","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191472032?lang=zh_tw&edition=fundamental","pubTime":"2026-10-22 12:01","pubTimestamp":1792641668,"startTime":"0","endTime":"0","summary":"药捷安康-B宣布，旗下产品Yochanra已获得中国国家药品监督管理局（NMPA）的附条件上市批准，适应症为晚期胆管癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677840119","title":"藥捷安康－Ｂ(02617)股價下跌5.072%，現價港幣$8.61","url":"https://stock-news.laohu8.com/highlight/detail?id=2677840119","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677840119?lang=zh_tw&edition=fundamental","pubTime":"2026-10-22 10:05","pubTimestamp":1792634700,"startTime":"0","endTime":"0","summary":"[下跌股]药捷安康－Ｂ(02617) 股价在上午10:05比前收市价下跌5.072%，现股价为港币$8.61。至目前为止，今日最高价为$9.09，而最低价为$8.61。总成交量为85.3万股，总成交金额为港币$752.685万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260929144019223_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260929144019223_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2610223378/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2610223378/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675565713","title":"藥捷安康－Ｂ(02617)股價上升5.036%，現價港幣$9.595","url":"https://stock-news.laohu8.com/highlight/detail?id=2675565713","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675565713?lang=zh_tw&edition=fundamental","pubTime":"2026-10-16 13:48","pubTimestamp":1792129680,"startTime":"0","endTime":"0","summary":"[上升股]药捷安康－Ｂ(02617) 股价在下午01:48比前收市价上升5.036%，现股价为港币$9.595。至目前为止，今日最高价为$9.595，而最低价为$9.26。总成交量为223.9万股，总成交金额为港币$2.11千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260929144021365_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260929144021365_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2610162900/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2610162900/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674833168","title":"藥捷安康－Ｂ(02617)股價上升5.065%，現價港幣$10.58","url":"https://stock-news.laohu8.com/highlight/detail?id=2674833168","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674833168?lang=zh_tw&edition=fundamental","pubTime":"2026-10-09 13:25","pubTimestamp":1791523500,"startTime":"0","endTime":"0","summary":"[上升股]药捷安康－Ｂ(02617) 股价在下午01:25比前收市价上升5.065%，现股价为港币$10.58。至目前为止，今日最高价为$10.58，而最低价为$9.81。总成交量为279.7万股，总成交金额为港币$2.861千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2610094386/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2610094386/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182209117","title":"藥捷安康-B更新9月股份變動月報表，股本保持穩定","url":"https://stock-news.laohu8.com/highlight/detail?id=1182209117","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182209117?lang=zh_tw&edition=fundamental","pubTime":"2026-10-05 17:17","pubTimestamp":1791191860,"startTime":"0","endTime":"0","summary":"药捷安康（南京）科技股份有限公司于2026年10月5日披露截至2026年9月30日的股份变动月报表，显示报告期内各类股份无新增发行或回购，整体股本保持稳定。报告期末，公司法定注册股本总额为人民币407,918,633元，其中H股法定注册股本为人民币312,687,673元，非上市普通股法定注册股本为人民币95,230,960元。H股奖励计划下已有2,442,000份股票期权结存数保持不变。另有2026年H股奖励计划股份授权，但本月内未实际导致已发行股份总数变动。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671224139","title":"藥捷安康－Ｂ(02617)股價上升5.04%，現價港幣$10.63","url":"https://stock-news.laohu8.com/highlight/detail?id=2671224139","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671224139?lang=zh_tw&edition=fundamental","pubTime":"2026-09-30 10:39","pubTimestamp":1790735940,"startTime":"0","endTime":"0","summary":"[上升股]药捷安康－Ｂ(02617) 股价在上午10:39比前收市价上升5.04%，现股价为港币$10.63。至目前为止，今日最高价为$10.63，而最低价为$10.08。总成交量为212.75万股，总成交金额为港币$2.224千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260930720/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260930720/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669171299","title":"生物醫藥板塊強勢 勁方醫藥-B（02595）漲8.01% 機構指醫藥工業「十五五」規劃有標誌性意義","url":"https://stock-news.laohu8.com/highlight/detail?id=2669171299","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669171299?lang=zh_tw&edition=fundamental","pubTime":"2026-09-23 10:49","pubTimestamp":1790131753,"startTime":"0","endTime":"0","summary":"金吾财讯 | 生物医药板块强势，恒生生物科技、恒生医疗保健指数涨幅均超1%。消息面上，9月18日，工信部、国家发改委等十部门发布医药工业“十五五”规划，对首创新药、创新医疗器械、产业链自主可控与国际化等提出要求，积极鼓励创新药及其产业链，制药装备，精准诊疗产业链。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/MDgxZGVmMDU5NGQxM2FkZGQzODVkYTY4OWM4NjkxNzk5NzY4NzQ2MDU0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992289","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000320223.HKD","159938","BK1574","BK1515","02410","XBI","BK1161","HK0000320264.USD","BK1191","09939","01548","BK1576","399441","BK4585","02617","HK0000306701.USD","161726","06185","07666","06127","HK0000306685.HKD","02595","BK1141","BK1583","09966","BK4581","02126","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107407294","title":"藥捷安康-B2026年中期營收0.35億元，經調整淨虧損0.95億元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107407294","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107407294?lang=zh_tw&edition=fundamental","pubTime":"2026-09-21 20:13","pubTimestamp":1789992799,"startTime":"0","endTime":"0","summary":"2026年上半年，药捷安康-B实现营收人民币3545.50万元，而上年同期尚无收入。本期经调整净亏损约人民币0.95亿元，较上年同期的经调整净亏损进一步收窄。经营活动现金流出净额约为人民币1.06亿元，较上年同期的1.09亿元小幅改善。成本结构方面，报告期内研发投入约人民币1.10亿元，同比上升11.7%，研发投入占收入比超过3100%。管理费用约人民币2306.00万元，同比下降约16.1%。主要收入来自与合作及授权协议相关的一次性预付款收入合计人民币3545.50万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药捷安康-B2026年中期营收0.35亿元，经调整净亏损0.95亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669315301","title":"港股異動 | 藥捷安康-B(02617)升逾11% 替恩戈替尼mCRPC中國II期臨床完成首例給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315301","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669315301?lang=zh_tw&edition=fundamental","pubTime":"2026-09-21 10:37","pubTimestamp":1789958272,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，药捷安康-B(02617)涨超11%，截至发稿，涨11.37%，报11.17港元，成交额1.03亿港元。消息面上，9月18日晚，药捷安康公告，公司核心产品替恩戈替尼(捷恩泰®， Tinengotinib, TT-00420)联合新型内分泌治疗(NHT)用于经治后进展的转移性去势抵抗性前列腺癌(mCRPC)中国II期临床试验，于近日完成首例患者给药。此外，9月17日，药捷安康宣布，其核心产品捷恩泰®（替恩戈替尼片）首批产品正式从商业渠道发货，发往全国各地药房，捷恩泰®正式开启全国商业化供应，标志着这款全球首个解决FGFR抑制剂耐药的胆管癌靶向药即将陆续抵达全国各地患者手中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02617","KCAI","BK1161","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139010","title":"藥捷安康(02617.HK)替恩戈替尼獲納入CSCO膽道惡性腫瘤診療指南","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139010","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669139010?lang=zh_tw&edition=fundamental","pubTime":"2026-09-21 10:24","pubTimestamp":1789957440,"startTime":"0","endTime":"0","summary":"药捷安康(02617.HK) 公布，自研创新多靶点小分子激酶抑制剂“捷恩泰”(替恩戈替尼)，作为晚期胆道恶性肿瘤治疗的II级推荐2A类被纳入《中国临床肿瘤学会(CSCO)胆道恶性肿瘤诊疗指南》。替恩戈替尼已于今年8月6日在中国附条件获批上市，用于既往接受过系统性治疗和FGFR抑制剂治疗，且具有成纤维细胞生长因子受体(FGFR)2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-18 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250618173115303_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250618173115303_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1545457/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1545457/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669733136","title":"藥捷安康－Ｂ(02617)股價上升5.184%，現價港幣$10.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2669733136","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669733136?lang=zh_tw&edition=fundamental","pubTime":"2026-09-21 09:35","pubTimestamp":1789954500,"startTime":"0","endTime":"0","summary":"[上升股]药捷安康－Ｂ(02617) 股价在上午09:34比前收市价上升5.184%，现股价为港币$10.55。至目前为止，今日最高价为$10.55，而最低价为$10.24。总成交量为95.25万股，总成交金额为港币$989.4万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260921479/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR260921479/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668923201","title":"藥捷安康-B：捷恩泰獲納入CSCO膽道惡性腫瘤診療指南(2026)","url":"https://stock-news.laohu8.com/highlight/detail?id=2668923201","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668923201?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 20:05","pubTimestamp":1789733100,"startTime":"0","endTime":"0","summary":"9月18日，药捷安康-B（02617）发布公告，公司自主研发的捷恩泰?（替恩戈替尼）被纳入《中国临床肿瘤学会（CSCO）胆道恶性肿瘤诊疗指南（2026）》，作为晚期胆道恶性肿瘤治疗的II级推荐2A类。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878777228.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878777228.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142095939","title":"藥捷安康-B（02617）完成替恩戈替尼聯合NHT治療mCRPC中國Ⅱ期臨床首例給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1142095939","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142095939?lang=zh_tw&edition=fundamental","pubTime":"2026-09-18 18:55","pubTimestamp":1789728930,"startTime":"0","endTime":"0","summary":"2026年9月18日，药捷安康-B公告称，公司核心产品替恩戈替尼联合新型内分泌治疗用于经治后进展的转移性去势抵抗性前列腺癌中国Ⅱ期临床试验已完成首例患者给药。替恩戈替尼是全球首个同时抑制FGFR/JAK通路并已在mCRPC中显示临床疗效的多靶点小分子激酶抑制剂。替恩戈替尼单药治疗mCRPC已于2025年6月获得美国FDA快速通道资格。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":129,"code":"91000000","status":"200"}]}}